DE69630890D1 - Peptid-immitierende substanzen in der krebstherapie - Google Patents

Peptid-immitierende substanzen in der krebstherapie

Info

Publication number
DE69630890D1
DE69630890D1 DE69630890T DE69630890T DE69630890D1 DE 69630890 D1 DE69630890 D1 DE 69630890D1 DE 69630890 T DE69630890 T DE 69630890T DE 69630890 T DE69630890 T DE 69630890T DE 69630890 D1 DE69630890 D1 DE 69630890D1
Authority
DE
Germany
Prior art keywords
peptid
imitating
substances
cancer therapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630890T
Other languages
English (en)
Other versions
DE69630890T2 (de
Inventor
Sergio Sandrin
Farquar Mckenzie
Vasso Apostolopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Research Institute
Original Assignee
Austin Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Institute filed Critical Austin Research Institute
Application granted granted Critical
Publication of DE69630890D1 publication Critical patent/DE69630890D1/de
Publication of DE69630890T2 publication Critical patent/DE69630890T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69630890T 1995-09-27 1996-09-27 Peptid-immitierende substanzen in der krebstherapie Expired - Lifetime DE69630890T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN568095 1995-09-27
AUPN5680A AUPN568095A0 (en) 1995-09-27 1995-09-27 Anti-Galalpha(1,3)Gal antibody binding peptides
PCT/AU1996/000617 WO1997011715A1 (en) 1995-09-27 1996-09-27 Mimicking peptides in cancer therapy

Publications (2)

Publication Number Publication Date
DE69630890D1 true DE69630890D1 (de) 2004-01-08
DE69630890T2 DE69630890T2 (de) 2004-11-04

Family

ID=3790007

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630890T Expired - Lifetime DE69630890T2 (de) 1995-09-27 1996-09-27 Peptid-immitierende substanzen in der krebstherapie

Country Status (9)

Country Link
US (1) US6344203B1 (de)
EP (1) EP0859627B1 (de)
JP (1) JP4386209B2 (de)
AT (1) ATE255128T1 (de)
AU (3) AUPN568095A0 (de)
CA (1) CA2233447C (de)
DE (1) DE69630890T2 (de)
NZ (1) NZ318729A (de)
WO (2) WO1997011715A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
WO2000006194A2 (en) * 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2000077031A2 (en) * 1999-06-15 2000-12-21 University Health Network Muc1 ligands
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
CA2399026A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
ATE529123T1 (de) * 2002-04-15 2011-11-15 Oncothyreon Inc Synthetische glykolipopeptide als impfstoffe
ES2385032T3 (es) * 2002-04-22 2012-07-17 Recopharma Ab Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
BR0314471A (pt) * 2002-10-10 2005-08-02 Us Dept Veterans Affairs Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor
GB2395270B (en) 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005037261A1 (en) * 2003-10-14 2005-04-28 Biomira, Inc. Combination therapy for cancer
WO2005082458A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
NZ563466A (en) 2005-05-27 2009-12-24 Oncimmune Ltd Improved immunoassay methods
CN1301267C (zh) * 2005-06-21 2007-02-21 中国人民解放军军事医学科学院附属医院 Muc1粘蛋白的一个模拟表位肽及其编码dna与应用
PL2366400T3 (pl) 2005-06-28 2016-03-31 Oncothyreon Inc Sposób leczenia pacjentów szczepionką na bazie glikoproteiny mucynowej (MUC-1)
EP1857463A1 (de) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Neuroprotektive Wirkungen von Peptide
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
AU2008323853B8 (en) * 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
EP2560989B1 (de) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Glycopeptidepitope im zusammenhang mit krebs, antikörper und verfahren zur verwendung
BR112013021779A2 (pt) 2011-02-24 2017-09-19 Oncothyreon Inc vacina de glicolipopeptídeo baseada em muc1 com adjuvante.
WO2012135313A1 (en) * 2011-03-28 2012-10-04 University Of Massachusetts Compositions and methods for detecting allergy to a-gal epitopes
NZ623086A (en) 2011-09-30 2016-08-26 Dana Farber Cancer Inst Inc Therapeutic peptides
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
MX371187B (es) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Péptidos terapéuticos.
EP3925973A1 (de) * 2014-03-14 2021-12-22 Dana-Farber Cancer Institute, Inc. Impfstoffzusammensetzungen und verfahren zur wiederherstellung der nkg2d-wegfunktion gegen krebs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP1621627A3 (de) * 1993-03-16 2006-06-07 The Austin Research Institute Verwendung von Schwein gal-g(a)(1,3) Galaktosyltransferase für xenogene Therapien
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JP2833633B2 (ja) 1993-12-30 1998-12-09 インターナシヨナル・ビジネス・マシーンズ・コーポレーシヨン データ処理システム及び待ち行列管理方法
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides

Also Published As

Publication number Publication date
AU7079396A (en) 1997-04-17
AUPN568095A0 (en) 1995-10-26
DE69630890T2 (de) 2004-11-04
WO1997011715A1 (en) 1997-04-03
ATE255128T1 (de) 2003-12-15
US6344203B1 (en) 2002-02-05
AU707223B2 (en) 1999-07-08
EP0859627A1 (de) 1998-08-26
CA2233447C (en) 2011-11-29
JP2000506493A (ja) 2000-05-30
EP0859627B1 (de) 2003-11-26
EP0859627A4 (de) 1999-04-14
AU7079496A (en) 1997-04-17
JP4386209B2 (ja) 2009-12-16
WO1997011963A1 (en) 1997-04-03
CA2233447A1 (en) 1997-04-03
NZ318729A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
FI955552A (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
DK85786A (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
ATE223227T1 (de) Verwendung von lbp zur sepsistherapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition